In 1941, Hans Selye discovered that some steroid compounds produced anaesthesia. The following year he conducted experiments with 75 steroids which were dissolved in peanut oil and given intraperitoneally to partially hepatectomized rats. He stated, "the most striking fact which emerges from a perusal of the data is that all preparations that are known to possess hormonal properties are active as anaesthetics". Of all the preparations that he studied, pregnandione was the one that showed a particularly marked narcotic effect. Unfortunately pregnandione is almost insoluble in water which made intravenous administration difficult. Further research was performed using subcutaneous pregnandione in peanut oil on young rats. Anaesthesia was produced relatively quickly but the rats slept for 26 hours! This research led Laubach, P'an and Rudel to experiment with 21-hydroxypregnanedione sodium hemisuccinate (hydroxydione), a water soluble derivative of pregnandione. This compound was manufactured by the Pfizer company as Viadril and clinical trials were commenced in 1955 by F. J. Murphy and colleagues on 125 patients. They found it to be a satisfactory anaesthetic agent when used with nitrous oxide and oxygen, with or without opioids and muscle relaxants.
The following year further clinical trials were reported by R. A. Gordon and colleagues from Toronto General Hospital. "The drug is supplied as a white powder which is readily soluble in water. Since it is a soap, it tends to foam, and this characteristic can be a nuisance in the preparation of solutions. It is irritating to tissues and tends to produce thrombosis of the veins." They experimented with various dose and dilution regimens and found that the process became more difficult as the operations became longer. Several patients had intermittent doses throughout and four had continuous infusions. They found the induction period was long, about five minutes, and that intermittent doses had to be given before they were required due to this prolonged onset of action. However, the patients found the induction pleasant although three patients reported that the room turned green as they were going to sleep and one thought it turned red! Apart from this the only significant complication was venous thrombosis which occurred in 14% of patients, and a severe inflammatory reaction in one patient in whom the solution extravasated.
Various techniques were used to try to overcome the problem of thrombophlebitis, such as running large-volume dilute solutions as an infusion. However, generally this complicated and delayed the induction. Other formulations were tried and a substance called Pressuren (see cover photo) appeared briefly on the market. It was easier to dissolve but there were still problems with thrombophlebitis. These water-soluble steroids did not enjoy a long life as induction agents and work began again on fat-soluble steroids.
Glaxo Research examined 168 variants of pregnandione. One of their early promising derivatives produced unpleasant parasthesias and was abandoned. Research continued and eventually led to the development of Althesin (known experimentally as CT-1341, and Alfathesin in some countries), a combination of two steroids, alphaxolone and alphadolone acetate dissolved in the fat solvent, Cremophor EL. The alphadolone had little anaesthetic potency but increased the solubility of alphaxalone in Cremophor. The cover photo shows ampoules of CT-1341 and Althesin. Pharmacological studies were conducted by K. J. Childs on animals in 1971 and John Dundee and colleagues reported its clinical uses the following year. It became very popular in the United Kingdom and parts of Europe, but was never introduced into the United States. It was a good induction agent with minimal cardiovascular side-effects and rapid recovery rate. It also had minimal cumulative effects, which led to its use as an infusion both for anaesthesia and sedation. T. M. Savege, one of the early proponents of Althesin infusions, concluded "this intravenous technique is difficult to learn and does not always provide smooth, easily controlled anaesthesia. The principal complication is one of movement, thought the significance of this is not clear-patients otherwise appear adequately anaesthetized and the surgical procedure is seldom affected." His final conclusion was that "The advantage of intravenous anaesthesia is the elimination of anaesthetic gases and vapours. Complicated anaesthetic machines and vaporizers become unnecessary and atmospheric pollution is avoided. These advantages suggest that intravenous techniques will be increasingly adopted and perfected."
The principal problem with Althesin was the incidence of bronchospasm and cardiovascular collapse which was variously reported from 1 in 900 to 1 in 11,000. As problems developed with other drugs such as propanidid, which was also dissolved in Cremophor EL, it became apparent that the solvent was the probable cause of the anaphylactoid reactions. Users of the drug became more cautious and it was eventually withdrawn in 1984.
Further Glaxo research led to the development of minaxolone, another water-soluble steroid which resulted from changes to the pregnandione molecule. It produced a prolonged induction and a high incidence of muscle movements. Subsequent animal studies produced some queries about its carcinogenicity, and it was withdrawn during clinical trials.
The last steroid to be used clinically was pregnanolone, a water insoluble steroid which was presented in the early 1990s in a soya bean emulsion that had been used for parenteral nutrition. Initial clinical trials were quite favourable, but it did not have any striking new properties. It disappeared from the literature around 1995 but we cannot find any record of problems with this drug. It is likely that the popularity of other drugs, such as propofol, suspended any further research. It should also be noted that there is a problem marketing a naturally occurring substance. This may explain the drug companies' lack of enthusiasm for further research into steroid anaesthesia, despite the advent of better solvents for water insoluble substances. CHRISTINE BALL, ROD WESTHORPE Geoffrey Kaye Museum of Anaesthetic History
